A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / microl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics
- 05 Dec 2007 Status change from in progress to completed reported by ClinicalTrials.gov.
- 08 Dec 2005 New trial record.